Browse by Poster Presenter

Schedule at a Glance

Icon Legend

This session is not in your schedule.

This session is in your schedule. Click again to remove it.

Browse by Poster Presenter

Type here to filter the list

Y
Yadukumar, Lekha

University of Iowa Hospitals and Clinics
(P 371) CLINICAL PROFILE AND TREATMENT PATTERNS OF ANGIOSARCOMA IN THE REAL- WORLD SETTING: A SINGLE CENTER EXPERIENCE FROM 1991-2024.
Lekha Yadukumar
Favorite
Yaeger, Rona

Memorial Sloan Kettering Cancer Center
(P 415) A PHASE 1/2 TRIAL OF FOG-001, A FIRST-IN-CLASS DIRECT β-CATENIN:TCF4 INHIBITOR: SAFETY AND PRELIMINARY ANTITUMOR ACTIVITY IN PATIENTS WITH DESMOID TUMORS (DT)
Rona Yaeger
Favorite
Yakovich, Adam

Replimune Group
(P 439) AN OPEN LABEL MULTICENTER PHASE 2 STUDY WITH SAFETY LEAD IN OF INTRATUMORAL VUSOLIMOGENE ODERPAREPVEC IN COMBINATION WITH PEMBROLIZUMAB IN PATIENTS WITH ANGIOSARCOMA
Adam Yakovich
Favorite
Yalamanchili, Sudha

University of Texas MD Anderson Cancer Center
(P 83) OUTCOMES OF MULTIMODAL PERIOPERATIVE TREATMENT IN OSTEOSARCOMAS OF THE JAW
Sudha Yalamanchili
Favorite
Yanai, Risa

1) Department of Pediatric Oncology, National Cancer Center Hospital, Tokyo, Japan
(P 341) PROGNOSTIC RELEVANCE OF CYCLOPHOSPHAMIDE DOSE FOR HIGH-RISK RHABDOMYOSARCOMA IN ADULT PATIENTS TREATED WITH VAC THERAPY
Risa Yanai
Favorite
Yanez, Giussepe

Duke University School of Medicine
(P 214) FINANCIAL TOXICITY IN PATIENTS WITH A HISTORY OF EXTREMITY AND PELVIC SARCOMA TREATMENT
Giussepe Yanez
Favorite
Yang, Cui

Department of Surgery, Medical Faculty Mannheim, Mannheim School of Medicine, Heidelberg University
(P 165) EVALUATING LARGE LANGUAGE MODELS AS DECISION SUPPORT TOOLS IN MULTIDISCIPLINARY TUMOR BOARDS FOR GASTROINTESTINAL STROMAL TUMORS
Cui Yang
Favorite
(P 169) BENCHMARKING LARGE LANGUAGE MODELS VS MULTIDISCIPLINARY TUMOR BOARDS OF 21 SARCOMA CENTERS
Cui Yang
Favorite
(P 312) APOSST: A PROSPECTIVE TRIAL TO EVALUATE ACUPUNCTURE AFTER SURGERY OF EXTREMITY SOFT TISSUE TUMORS
Cui Yang
Favorite
Yang, Eunkyu

Department of Orthopaedic surgery, Seoul National University Hospital
(P 09) ESTABLISHMENT AND CHARACTERIZATION OF 18 SARCOMA CELL LINES: UNRAVELING THE MOLECULAR MECHANISMS OF DOXORUBICIN RESISTANCE IN SARCOMA CELL LINES
Eunkyu Yang
Favorite
(P 66) ARHGEF4 EXPRESSION IN SOFT TISSUE SARCOMA CORRELATES WITH LOCAL GROWTH PATTERN: WHOLE TRANSCRIPTOME SEQUENCING ON SPATIALLY SEPARATED REGIONS, PATIENT-DERIVED MODELS, AND ORTHOTOPIC IN VIVO ANALYSIS
Eunkyu Yang
Favorite
(P 399) LATE LOCAL RECURRENCE (>5YEARS) OF SOFT TISSUE SARCOMA OF THE EXTREMITIES AND TRUNK WALL: PREDICTIVE FACTORS AND ONCOLOGIC OUTCOMES
Eunkyu Yang
Favorite
Yang, Hao

Memorial Sloan Kettering Cancer Center
(P 273) RADIOMIC PREDICTORS OF SPONTANEOUS PNEUMOTHORAX DURING TYROSINE KINASE INHIBITOR THERAPY FOR LUNG METASTASES
Hao Yang
Favorite
Yang, Linjun

Mayo Clinic, Rochester
(P 166) LARGE LANGUAGE MODEL EXTRACTION OF STRUCTURED DATA IN UNSTRUCTURED SARCOMA PATHOLOGY NOTES: A PILOT STUDY
Linjun Yang
Favorite
(P 167) LARGE LANGUAGE MODEL EXTRACTION OF STRUCTURED DATA FROM UNSTRUCTURED RADIATION ONCOLOGY NOTES: A PILOT STUDY
Linjun Yang
Favorite
Yang, Liping

Oregon State University
(P 19) SERUM EXOSOMES IDENTIFY AN ABERRANT PROTEOMIC SIGNATURE IN CANINE OSTEOSARCOMA PRECEDING METASTATIC PROGRESSION
Liping Yang
Favorite
Yang, Valerie

OncoCare Cancer Centre
(P 53) ESTABLISHMENT AND CHARACTERISATION OF LIPOSARCOMA-DERIVED CELLS AS RELEVANT PRE-CLINICAL MODELS FOR TARGET DISCOVERY
Valerie Yang
Favorite
Yang, Xiaoqian

University of Miami
(P 117) THERAPEUTIC POTENTIAL OF DOXORUBICIN AND DASATINIB COMBINATION IN OSTEOSARCOMA
Xiaoqian Yang
Favorite
(P 131) GLUCOSE TRANSPORTER 1 (GLUT1) INHIBITION DECREASES THE GROWTH AND PROLIFERATION OF CHONDROSARCOMA
Xiaoqian Yang
Favorite
Yang, Xiaoyan

Kura Oncology, Inc.
(P 423) ZIFTOMENIB IN COMBINATION WITH IMATINIB IN ADVANCED GASTROINTESTINAL STROMAL TUMORS (GIST) AFTER IMATINIB FAILURE: PHASE 1A/B STUDY OF SAFETY, PHARMACOKINETICS, AND ANTITUMOR ACTIVITY
Xiaoyan Yang
Favorite
Yang, Yuqin

Department of Laboratory Animal Center, Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine
(P 07) A LIVING MULTI-OMICS BIOBANK OF PATIENT-DERIVED XENOGRAFT MODELS FOR SARCOMA
Yuqin Yang
Favorite
Yang, Zecheng

The University of Texas MD Anderson Cancer Center
(P 391) ATRX LOSS BLOCKS THE DIFFERENTIATION OF MESENCHYMAL STEM CELLS AND ADVANCES UNDIFFERENTIATED SARCOMA DEVELOPMENT
Zecheng Yang
Favorite
Yan, Wangjun

Fudan University Shanghai Cancer Center, Shanghai, China
(P 361) PEXIDARTINIB FOR THE TREATMENT OF TENOSYNOVIAL GIANT CELL TUMORS: CLINICAL EXPERIENCE FROM FIVE CHINESE PATIENTS
Wangjun Yan
Favorite
Yao, Jun

The University of Texas MD Anderson Cancer Center
(P 54) PRECLINICAL MODELS REVEALING MDM2-P53 INTERACTION AND DEPENDENCY FOR TUMOR CELL SURVIVAL IN WELL-DIFFERENTIATED (WD) AND DEDIFFERENTIATED (DD) LIPOSARCOMA (LPS).
Jun Yao
Favorite
(P 391) ATRX LOSS BLOCKS THE DIFFERENTIATION OF MESENCHYMAL STEM CELLS AND ADVANCES UNDIFFERENTIATED SARCOMA DEVELOPMENT
Jun Yao
Favorite
Yao, Lan

Department of Anesthesiology,Peking University International Hosptial,Beijing
(P 469) THE IMPACT OF PREOPERATIVE ANEMIA ON POSTOPERATIVE COMPLICATIONS AND SHORT-TERM PROGNOSIS IN RETROPERITONEAL TUMOR SURGERY PATIENTS.
Lan Yao
Favorite
Yao, Wantong

The University of Texas MD Anderson Cancer Center
(P 54) PRECLINICAL MODELS REVEALING MDM2-P53 INTERACTION AND DEPENDENCY FOR TUMOR CELL SURVIVAL IN WELL-DIFFERENTIATED (WD) AND DEDIFFERENTIATED (DD) LIPOSARCOMA (LPS).
Wantong Yao
Favorite
(P 391) ATRX LOSS BLOCKS THE DIFFERENTIATION OF MESENCHYMAL STEM CELLS AND ADVANCES UNDIFFERENTIATED SARCOMA DEVELOPMENT
Wantong Yao
Favorite
YAP, Zheng Xi

National University of Singapore
(P 53) ESTABLISHMENT AND CHARACTERISATION OF LIPOSARCOMA-DERIVED CELLS AS RELEVANT PRE-CLINICAL MODELS FOR TARGET DISCOVERY
Zheng Xi YAP
Favorite
Yaron, Tomer

Weill Cornell Medicine
(P 198) EXPLOITING METABOLIC DYSREGULATION IN SUCCINATE DEHYDROGENASE-DEFICIENT GASTROINTESTINAL STROMAL TUMOR
Tomer Yaron
Favorite
Yassin, Samer

Northwestern University Feinberg School of Medicine
(P 183) ACTIONABLE GENOMICS IN GASTROINTESTINAL STROMAL TUMORS LACKING KIT OR PDGFRA MUTATIONS.
Samer Yassin
Favorite
(P 236) EXCEPTIONAL RESPONSE TO COMBINATION IMMUNOTHERAPY WITH YH001 AND ENVAFOLIMAB IN METASTATIC SARCOMA.
Samer Yassin
Favorite
Yeager, Nicholas

Department of Hematology/Oncology, Nationwide Children's Hospital
(P 264) RARE CASE OF INFLAMMATORY MYOFIBROBLASTIC TUMOR (IMT) IN NEWBORN
Nicholas Yeager
Favorite
Yechieli, Raphael

University of Miami, Department of Radiation Oncology
(P 289) SIX YEAR FOLLOW-UP ON CIVASHEET® USE FOR SOFT TISSUE SARCOMA: A SINGLE INSTITUTION EXPERIENCE
Raphael Yechieli
Favorite
Ye, Fei

Miller School of Medicine, University of Miami
(P 151) SHOULD WE USE ADJUVANT CHEMOTHERAPY IN PATIENTS WITH LOCALIZED DEDIFFERENTIATED CHONDROSARCOMA (DDCS) OF THE PELVIS? AN ANALYSIS BY THE PELVIC DDCS STUDY GROUP
Fei Ye
Favorite
Ye, Zhaoming

Orthopedics, The Second Affiliated Hospital Zhejiang University School of Medicine
(P 128) ISOCITRATE DEHYDROGENASE 1 (IDH1) MUTATION TESTING IN THE PHASE 3 STUDY OF IVOSIDENIB VS PLACEBO IN IDH1-MUTANT CONVENTIONAL CHONDROSARCOMA (CHONQUER)
Zhaoming Ye
Favorite
yi, liu

Anesthesiology Department, Shanxi Cancer Hospital
(P 469) THE IMPACT OF PREOPERATIVE ANEMIA ON POSTOPERATIVE COMPLICATIONS AND SHORT-TERM PROGNOSIS IN RETROPERITONEAL TUMOR SURGERY PATIENTS.
liu yi
Favorite
Yi, Min

MD Anderson Cancer Center
(P 351) THE ROLE OF SOCIOECONOMIC DISPARITIES ON SURVIVAL OUTCOMES IN MALIGNANT PERIPHERAL NERVE SHEATH TUMORS
Min Yi
Favorite
Ying, Haoqiang

MD Anderson Cancer Center
(P 54) PRECLINICAL MODELS REVEALING MDM2-P53 INTERACTION AND DEPENDENCY FOR TUMOR CELL SURVIVAL IN WELL-DIFFERENTIATED (WD) AND DEDIFFERENTIATED (DD) LIPOSARCOMA (LPS).
Haoqiang Ying
Favorite
(P 391) ATRX LOSS BLOCKS THE DIFFERENTIATION OF MESENCHYMAL STEM CELLS AND ADVANCES UNDIFFERENTIATED SARCOMA DEVELOPMENT
Haoqiang Ying
Favorite
Yin, Jun

Moffitt Cancer Center
(P 426) A PHASE I/II TRIAL USING RNA LIPID NANOPARTICLES FOR RECURRENT OSTEOSARCOMA: A REPORT FROM THE NATIONAL PEDIATRIC CANCER FOUNDATION
Jun Yin
Favorite
Yohe, Marielle

National Cancer Institute
(P 405) PAN-RAS INHIBITION AS A NOVEL THERAPEUTIC STRATEGY FOR RAS-DRIVEN RHABDOMYOSARCOMA
Marielle Yohe
Favorite
Yokoyama, Nobuhiko

Kyushu University
(P 472) LANDSCAPE OF ULTRA-RARE SARCOMAS: A NATIONWIDE STUDY FOR EPIDEMIOLOGY AND PROGNOSIS
Nobuhiko Yokoyama
Favorite
Yonemori, Kan

National Cancer Center Hospital
(P 128) ISOCITRATE DEHYDROGENASE 1 (IDH1) MUTATION TESTING IN THE PHASE 3 STUDY OF IVOSIDENIB VS PLACEBO IN IDH1-MUTANT CONVENTIONAL CHONDROSARCOMA (CHONQUER)
Kan Yonemori
Favorite
(P 341) PROGNOSTIC RELEVANCE OF CYCLOPHOSPHAMIDE DOSE FOR HIGH-RISK RHABDOMYOSARCOMA IN ADULT PATIENTS TREATED WITH VAC THERAPY
Kan Yonemori
Favorite
(P 434) A FIRST-IN-HUMAN PHASE 1, MULTICENTER, OPEN-LABEL STUDY OF M3554, A NOVEL ANTI-GD2 ANTIBODY-DRUG CONJUGATE, IN PATIENTS WITH ADVANCED SOLID TUMORS
Kan Yonemori
Favorite
yongjie, chen

Department of Anesthesiology,Peking University International Hosptial,Beijing
(P 469) THE IMPACT OF PREOPERATIVE ANEMIA ON POSTOPERATIVE COMPLICATIONS AND SHORT-TERM PROGNOSIS IN RETROPERITONEAL TUMOR SURGERY PATIENTS.
chen yongjie
Favorite
Yong, Taylor

Texas Tech University Health Science Center El Paso
(P 78) MENTAL HEALTH DISORDERS FOLLOWING PATHOLOGICAL FRACTURE: A RETROSPECTIVE COHORT STUDY
Taylor Yong
Favorite
Yoon, Janet

City of Hope Comprehensive Cancer Center
(P 315) ANALYSIS OF CHANGES IN T2-WEIGHTED SIGNAL INTENSITY AND TUMOR VOLUME AND EXPOSURE-RESPONSE IN THE RINGSIDE PHASE 2 STUDY OF VAREGACESTAT FOR DESMOID TUMORS
Janet Yoon
Favorite
(P 410) SUBGROUP ANALYSIS OF THE PHASE 2 PART OF THE RINGSIDE PHASE 2/3 TRIAL OF VAREGACESTAT FOR TREATMENT OF DESMOID TUMORS
Janet Yoon
Favorite
(P 452) EFFECTIVENESS OF ERIBULIN FOR MYXOID PLEOMORPHIC LIPOSARCOMA: INSIGHTS FROM A PATIENT-DERIVED MODEL AND CLINICAL TRANSLATION IN A PATIENT WITH ADVANCED DISEASE
Janet Yoon
Favorite
Yoshida, Akihiko

Department of Pathology, National Cancer Center Hospital, Tokyo, Japan
(P 341) PROGNOSTIC RELEVANCE OF CYCLOPHOSPHAMIDE DOSE FOR HIGH-RISK RHABDOMYOSARCOMA IN ADULT PATIENTS TREATED WITH VAC THERAPY
Akihiko Yoshida
Favorite
You, Daoqi

Memorial Sloan Kettering Cancer Center
(P 08) BUILDING A MEDICAL DONATION NETWORK TO ENHANCE DEVELOPMENT OF PEDIATRIC TUMOR MODELS
Daoqi You
Favorite
(P 25) IDENTIFICATION AND VALIDATION OF NON-GENETICALLY ENCODED VULNERABILITIES IN EWING SARCOMA
Daoqi You
Favorite
(P 48) PRECLINICAL ACTIVITY OF MEK INHIBITION IN COMBINATION WITH CHEMOTHERAPY IN MALIGNANT PERIPHERAL NERVE SHEATH TUMOR
Daoqi You
Favorite
(P 237) DEVELOPMENT OF EPHA2 CAR T CELL THERAPY FOR OSTEOSARCOMA
Daoqi You
Favorite
(P 267) THE RAF/MEK INHIBITOR VS-6766 SHOWS EFFICACY IN RAS-MUTANT PEDIATRIC PRECLINICAL XENOGRAFT MODELS- A REPORT FROM THE PEDIATRIC PRECLINICAL IN VIVO TESTING CONSORTIUM
Daoqi You
Favorite
You, James

The University of Texas MD Anderson Cancer Center
(P 391) ATRX LOSS BLOCKS THE DIFFERENTIATION OF MESENCHYMAL STEM CELLS AND ADVANCES UNDIFFERENTIATED SARCOMA DEVELOPMENT
James You
Favorite
Young, Eleanor

University of Michigan
(P 24) THE SIRTUIN SIRT5 SUPPORTS EWING SARCOMA SURVIVAL VIA REGULATION OF EWS-FLI1 STABILITY AND ACTIVITY
Eleanor Young
Favorite
Youn, Susie

University of British Columbia
(P 178) TREATMENT RESPONSE AND SURVIVAL OUTCOMES IN GASTROINTESTINAL STROMAL TUMORS FOLLOWING NEOADJUVANT THERAPY
Susie Youn
Favorite
Yovell, Jonathan

Immunome, Inc.
(P 315) ANALYSIS OF CHANGES IN T2-WEIGHTED SIGNAL INTENSITY AND TUMOR VOLUME AND EXPOSURE-RESPONSE IN THE RINGSIDE PHASE 2 STUDY OF VAREGACESTAT FOR DESMOID TUMORS
Jonathan Yovell
Favorite
(P 410) SUBGROUP ANALYSIS OF THE PHASE 2 PART OF THE RINGSIDE PHASE 2/3 TRIAL OF VAREGACESTAT FOR TREATMENT OF DESMOID TUMORS
Jonathan Yovell
Favorite
Yuan, Ying

Deciphera Pharmaceuticals, LLC
(P 424) AN OPEN-LABEL PHASE 1/2 STUDY OF DCC-3009 MONOTHERAPY IN PATIENTS (PTS) WITH ADVANCED GASTROINTESTINAL STROMAL TUMOR (GIST)
Ying Yuan
Favorite
Yu, Austin

Samaritan Health Services
(P 113) ASSESSING TREATMENT OUTCOMES OF CHONDROMYXOID FIBROMA: A CASE SERIES
Austin Yu
Favorite
Yustein, Jason

Emory University School of Medicine, Children's Healthcare of Atlanta
(P 21) EXAMINING THE THERAPEUTIC EFFECT OF TBL1/ β-CATENIN TARGETED COMBINATION THERAPIES ON METASTATIC OSTEOSARCOMA
Jason Yustein
Favorite
Yu, Ziyang

Parabilis Medicines
(P 415) A PHASE 1/2 TRIAL OF FOG-001, A FIRST-IN-CLASS DIRECT β-CATENIN:TCF4 INHIBITOR: SAFETY AND PRELIMINARY ANTITUMOR ACTIVITY IN PATIENTS WITH DESMOID TUMORS (DT)
Ziyang Yu
Favorite